Stepping Back From The Cliff Edge: UK Industry Welcomes Northern Ireland Brexit Extension
Executive Summary
Companies supplying into Northern Ireland now have more time to prepare for post-Brexit regulatory changes in areas like batch testing, imports and Falsified Medicines Directive requirements. UK industry association, PAGB, in a joint statement with five other pharmaceutical industry associations, including AESGP, describes it as a step in the right direction, but also warns that there is still much work to do.
You may also be interested in...
Brexit To Bring Regulatory Duplication, Possible Disruptions For UK Cosmetics Interests
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
No Deal Brexit Could Mean 'Considerable Obstacles' For German OTC Exports
The dangers of a hard Brexit, a welcome delay to the EU Medical Devices Regulation and the impact of the coronavirus on the German OTC market all feature in this exclusive HBW Insight catch up with Germany's self-medication industry association, the BAH.
How To Get A ‘Great Britain’ Drug Approval In 2021
So much will change on the regulatory front next year that the UK drug regulator, the MHRA, has had to issue dozens of new guidance documents to help pharma and biotech firms navigate the new requirements and assessment routes. A key consideration is how the UK will handle centralized EU applications that are still pending on 31 December.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: